246 related articles for article (PubMed ID: 15300425)
1. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.
Gao Z; Biersack HJ; Ezziddin S; Logvinski T; An R
J Cancer Res Clin Oncol; 2004 Nov; 130(11):649-56. PubMed ID: 15300425
[TBL] [Abstract][Full Text] [Related]
2. [Targeted radionuclide therapy for patients with metastatic medullary thyroid carcinoma].
Gao ZR; An R; Zhang YX; Biersack HJ
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):621-4. PubMed ID: 17236560
[TBL] [Abstract][Full Text] [Related]
3. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).
Kurtaran A; Leimer M; Kaserer K; Yang Q; Angelberger P; Niederle B; Virgolini I
Nucl Med Biol; 1996 May; 23(4):503-7. PubMed ID: 8832707
[TBL] [Abstract][Full Text] [Related]
4. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Bomanji JB; Papathanasiou ND
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
[TBL] [Abstract][Full Text] [Related]
5. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
Bodei L; Handkiewicz-Junak D; Grana C; Mazzetta C; Rocca P; Bartolomei M; Lopera Sierra M; Cremonesi M; Chinol M; Mäcke HR; Paganelli G
Cancer Biother Radiopharm; 2004 Feb; 19(1):65-71. PubMed ID: 15068613
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan.
Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C
Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753
[TBL] [Abstract][Full Text] [Related]
7. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma.
Kurtaran A; Scheuba C; Kaserer K; Schima W; Czerny C; Angelberger P; Niederle B; Virgolini I
J Nucl Med; 1998 Nov; 39(11):1907-9. PubMed ID: 9829581
[TBL] [Abstract][Full Text] [Related]
8. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
Pasieka JL; McEwan AJ; Rorstad O
Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
[TBL] [Abstract][Full Text] [Related]
9. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Mure A; Plouin PF; Caillou B; Parmentier C
J Nucl Med; 1995 Jan; 36(1):1-6. PubMed ID: 7799058
[TBL] [Abstract][Full Text] [Related]
10. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.
Waldherr C; Schumacher T; Pless M; Crazzolara A; Maecke HR; Nitzsche EU; Haldemann A; Mueller-Brand J
Nucl Med Commun; 2001 Jun; 22(6):673-8. PubMed ID: 11403179
[TBL] [Abstract][Full Text] [Related]
11. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
12. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
13. [Detection of neural crest tumors by 123I-MIBG scintigraphy].
Ikekubo K; Hino M; Ootsuka H; Ito H; Yamaguchi H; Dan Y; Masui Y; Bito S; Ohta K; Saiki Y
Kaku Igaku; 1994 Nov; 31(11):1357-64. PubMed ID: 7837704
[TBL] [Abstract][Full Text] [Related]
14. [Accumulation of radioactivity in the lung after 111In-octreotide scintigraphy].
Schleicher UM; Cremerius U; Schubert H
Rofo; 1998 Apr; 168(4):404-6. PubMed ID: 9589108
[No Abstract] [Full Text] [Related]
15. Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma.
Hoefnagel CA; Delprat CC; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):334-6. PubMed ID: 1823851
[TBL] [Abstract][Full Text] [Related]
16. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
Beukhof CM; Brabander T; van Nederveen FH; van Velthuysen MF; de Rijke YB; Hofland LJ; Franssen GJH; Fröberg LAC; Kam BLR; Visser WE; de Herder WW; Peeters RP
BMC Cancer; 2019 Apr; 19(1):325. PubMed ID: 30953466
[TBL] [Abstract][Full Text] [Related]
17. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
[TBL] [Abstract][Full Text] [Related]
18. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
19. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
Breeman WA; van Hagen PM; Kwekkeboom DJ; Visser TJ; Krenning EP
Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
